Posts tagged Martin Olovsson
New agreement expands collaboration between OnDosis and Tiefenbacher Group, opening a new chapter in precision medicine for rare disease and transplantation medicine
New agreement expands collaboration between OnDosis and Tiefenbacher Group, opening a new chapter in precision medicine for rare disease and transplantation medicine

Swedish Life science company OnDosis and German B2B pharmaceutical company Tiefenbacher Group initiate four new innovative development projects targeting ADHD, rare diseases and transplantation medicine. The idea is to improve the health and everyday lives of millions of patients by giving them access to finely tuned and individualized medicine.

Read More
PressreleaseMelisha LinnellOnDosis, ​Tiefenbacher, Group, ADHD, Dr. Kristian Ruepp, Martin Olovsson, Life Science, Pharmaceutical medicin, digital therapeutics, personalised medicine
OnDosis completes a private placement of SEK 92 million led by Aeternum Capital
OnDosis completes a private placement of SEK 92 million led by Aeternum Capital

OnDosis, a Swedish Life science company developing a new device technology platform, announced today that the Company has completed a pre-IPO private placement of SEK 92 million. Investors in the private placement include Aeternum Capital, DIG Investment and Albonja.

Read More
PressreleaseMelisha LinnellMartin Olovsson, digital therapeutics, OnDosis, ​Tiefenbacher Group, Life Science, Aeternum Management, Danske Bank, Staffan Ternström, personalised medicine, private placement